Question 1

What is PMDA?

Accepted Answer

PMDA is Japan’s Pharmaceuticals and Medical Devices Agency. It conducts scientific reviews of pharmaceuticals, medical devices, in vitro diagnostics and regenerative medicine products, and supports post-market safety activities. Japan’s Ministry of Health, Labor and Welfare is responsible for approval decisions and related administrative actions. PMDA also offers consultation services, with fees depending on the consultation type.

Question 2

Can PMDA consider global clinical data?

Accepted Answer

Yes. PMDA may consider global clinical data, but acceptance depends on the product, indication, study design, endpoints, patient population, ethnic sensitivity, safety profile and relevance to the Japanese treatment environment. Some programs may rely substantially on global evidence, while others may need Japan-specific data or additional analysis. Companies should assess this early in order to make the most efficient choices.

Question 3

Do foreign companies always need Japanese clinical trials?

Accepted Answer

No. Japanese clinical trials are not always required. The need depends on the product, regulatory pathway, existing evidence and relevance of the data to Japanese patients. Some programs may use global data, while others may require local participants, additional studies or bridging analysis. The evidence strategy should be assessed early because it can affect approval timing, development cost, reimbursement and the commercial case for Japan.

Question 4

How long does PMDA approval take?

Accepted Answer

PMDA review timelines vary by product, pathway and submission quality. A standard new drug and new device review have a 12-month target, but accelerated pathways, complex evidence packages or additional questions can change the timing. In 2025, for the first time ever, Japan’s average new drug review period was faster than both the FDA and the EMA.

Question 5

What regulatory missteps steps do foreign companies often make?

Accepted Answer

Common regulatory missteps include considering Japan much later than their US/global strategy, underestimating Japanese documentation and quality requirements and separating regulatory planning from reimbursement and commercial strategy. Another risk is choosing a local partner before the product pathway and responsibilities are clear. Companies should assess the full Japan route before fixing development plans or partner arrangements, keeping their options available for as long as possible.

Question 6

How should foreign companies approach Japan regulatory strategy?

Accepted Answer

A Japan regulatory strategy should begin with the product profile, indication, patient population, available evidence and intended commercial model. Companies should assess whether global data may support a filing, what additional local work could be required, which Japan-based authorization and quality roles are needed, and how the regulatory pathway affects reimbursement and launch timing. Early PMDA consultation may be appropriate for product-specific questions.

Question 7

Why is local regulatory coordination important in Japan?

Accepted Answer

Local regulatory coordination matters because Japan has specific requirements for documentation, communication, quality systems, local representation and post-market responsibilities. A capable Japan-based team can coordinate consultations, translations, document creation, support your strategizing and decision-making and handle the submission on your behalf. The Japan-based team will also need to support local KOL relations and reimbursement pricing strategy. The required support depends on the product, pathway and responsibilities assigned to each party.

FAQ